Inflammatory Bowel Disease Therapeutics: Market Research Report
This report analyzes the Global market for Inflammatory Bowel Disease Therapeutics in US$ Million.
Annual estimates and forecasts are provided for the period 2006 through 2015.
The report profiles 69 companies including Abbott Laboratories, Biogen Idec, Inc., Cosmo Pharmaceuticals SpA, ChemoCentryx, Inc., Dr. Falk Pharma GmbH, Eisai Co., Ltd., Elan Corporation, plc, Ferring Pharmaceuticals A/S, GlaxoSmithKline plc, Johnson & Johnson, Centocor Ortho Biotech, Inc, Kyorin Pharmaceutical Co., Ltd., Merck Serono, Millennium Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Pharmaceutical Co.Ltd., Prometheus Laboratories, Inc., Shire plc, UCB SA, and Wyeth.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
Annual estimates and forecasts are provided for the period 2006 through 2015.
The report profiles 69 companies including Abbott Laboratories, Biogen Idec, Inc., Cosmo Pharmaceuticals SpA, ChemoCentryx, Inc., Dr. Falk Pharma GmbH, Eisai Co., Ltd., Elan Corporation, plc, Ferring Pharmaceuticals A/S, GlaxoSmithKline plc, Johnson & Johnson, Centocor Ortho Biotech, Inc, Kyorin Pharmaceutical Co., Ltd., Merck Serono, Millennium Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Pharmaceutical Co.Ltd., Prometheus Laboratories, Inc., Shire plc, UCB SA, and Wyeth.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.INDUSTRY OVERVIEW
Introduction
Biological Drugs Lead the IBD Therapeutics Bandwagon
Leading Biological Drugs Approved for Treatment of Crohn’s Disease
Year of Approval for Leading Drugs in Crohn’s Disease Treatment
Impact of the Economic Recession on the Pharmaceutical Industry
Recession Brings Drug Development Efforts Under Siege
Biotech Bankruptcies Rife in the Current Economic Downturn
Current and Future Analysis
Regional Market Overview
United States
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs Market
Key Ulcerative Colitis Drugs in the US (2006)
Canada
Key Challenges Lie ahead
Productivity Loss to the Nation
Australia
Japan
Europe
Increasing Awareness to Drive Market Growth
United Kingdom
2.IBD - AN OVERVIEW
Prevalence and Incidence
Women More Susceptible to IBD
Etiology of Inflammatory Bowel Disease
Genetic Predisposition
Environmental Factors
IBD – A Health and Social Burden
Inflammatory Bowel Disease Types
Crohn's Disease (CD)
Ulcerative Colitis (UC)
Clinical Manifestations
Signs and Symptoms
Diagnosis
Pathogenesis
Outcomes
Treatment Strategies
Step I (Aminosalicylates)
5-AMINOSALICYLIC ACID (5-ASA) DERIVATIVES AND AVAILABLE BRANDS IN THE US MARKET
Step II (Antibiotics)
Step III (Corticosteroids)
Available Corticosteroidal Drugs As per Mode of Administration
Step IV (Immuno-modifying Agents)
Overview of Select Biological Drugs
Infliximab (Remicade)
Adalimumab (Humira)
Certolizumab pegol (Cimzia)
Natalizumab (Tysabri)
Step V (Experimental Medication)
Experimental Medication Drugs for IBD with Dosage Settings
Ileal Pouch recommended in Conditions of Ulcerative Colitis
Comparing Crohn’s Disease and Ulcerative Colitis
Comparison of Characteristics of Ulcerative Colitis and Crohn’s Disease
3.PRODUCT INNOVATIONS/LAUNCHES
Procter & Gamble Pharmaceuticals Introduces Asacol HD
Exagen Diagnostics Introduces eXaIBS Test and eXaIBD Test
Cimzia® Receives FDA Nod for Treating Crohn’s Disease
Kyorin Pharmaceutical Launches Pentasa Tablets 500
Xian-Janssen Introduces Remicade, Branded infliximab in China
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease
Salix and Watson to Launch COLAZAL® Authorized Generic
4.RECENT INDUSTRY ACTIVITY
GlaxoSmithKline Enters into Partnerships with Biotica, Dynavax, and Archemix
Sequenom Buys AttoSense Portfolio and Other Assets from SensiGen
Zeria Pharmaceutical to Take Over Tillotts Pharma
Meridian Bioscience Europe Signs Agreement with BUHLMANN Laboratories
Sosei Group Inks Deal with Biocopea
UCB Receives FDA Approval for Cimzia
Regeneron Pharmaceuticals and Sanofi-aventis Extend Global Collaboration
Celldex Therapeutics Acquires CuraGen
Onyx Pharmaceuticals Acquires Proteolix
Roche Acquires ARIUS Research, Inc.
Nycomed Inks Agreement with Immunomedics for Veltuzumab
Archemix Inks Deal with GlaxoSmithKline
Boehringer to Takeover Actimis
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals
The Asian Institute of Gastroenterology Establishes New facility
TPG Capital Acquires Axcan Pharma
Cosmo Pharmaceuticals Collaborates with Santarus
BioLineRx Inks License Agreement with Yissum
Salix Pharmaceuticals Secures FDA Approval for APRISO™
Omeros Inks Agreement with Affitech
GlaxoSmithKline Enters into Strategic Alliance with Regulus Therapeutics
Roche to Take Over Piramed
Evotec Acquires Renovis
Takeda Pharmaceutical Acquires Millennium Pharmaceuticals
GlaxoSmithKline Takes Over Sirtris Pharmaceuticals
Boehringer Ingelheim Inks Agreement with Actimis Pharmaceuticals
GlaxoSmithKline Enters into a Strategic Alliance with Archemix
Pipex Pharmaceuticals Buys Oral dnaJP1
Emergent BioSolutions Acquires AVANIR’s Anthrax Monoclonal Antibody Collection
Ferring Inks License Agreement with Conaris
ZymoGenetics and Merck Serono Restructure Their Partnership
Evotec Acquires Renovis
ViroPharma Acquires Lev Pharmaceuticals
TPG Capital Inks Agreement to Acquire Axcan Pharma
Meyer Pharmaceuticals Inks Agreement with AnGes
The School of Pharmacy Enters Into Collaboration with Tillotts Pharma
Sequenom Inks Collaborative Agreement with SensiGen
Evotec Signs Collaborative Agreement with Interprotein
Shire Obtains Approval from FDA for LIALDA™ (mesalamine)
Amgen Acquires Avidia
Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals
5.FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories (US)
Biogen Idec, Inc. (US)
Cosmo Pharmaceuticals SpA (Italy)
ChemoCentryx, Inc. (US)
Dr. Falk Pharma GmbH (Germany)
Eisai Co., Ltd. (Japan)
Elan Corporation, plc (Ireland)
Ferring Pharmaceuticals A/S (Denmark)
GlaxoSmithKline plc (UK)
Johnson & Johnson (US)
Centocor Ortho Biotech, Inc. (US)
Kyorin Pharmaceutical Co., Ltd. (Japan)
Merck Serono (Switzerland)
Millennium Pharmaceuticals, Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co. Ltd. (Japan)
Prometheus Laboratories, Inc. (US)
Shire Plc (UK)
UCB SA (Belgium)
Wyeth (US)
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 69 (including Divisions/Subsidiaries - 77)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.INDUSTRY OVERVIEW
Introduction
Biological Drugs Lead the IBD Therapeutics Bandwagon
Leading Biological Drugs Approved for Treatment of Crohn’s Disease
Year of Approval for Leading Drugs in Crohn’s Disease Treatment
Impact of the Economic Recession on the Pharmaceutical Industry
Recession Brings Drug Development Efforts Under Siege
Biotech Bankruptcies Rife in the Current Economic Downturn
Current and Future Analysis
Table 1. World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease Therapeutics by Disease Type – Crohn’s Disease and Ulcerative Colitis Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 2. World 9-Year Perspective for Inflammatory Bowel Disease Therapeutics by Disease Type – Percentage Breakdown of Dollar Sales for Crohn’s Disease and Ulcerative Colitis Markets for the Years 2006, 2009 & 2015
Regional Market Overview
United States
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs Market
Key Ulcerative Colitis Drugs in the US (2006)
Table 3. US Ulcerative Colitis Drugs Market (2007 & 2008): Percentage Breakdown of Prescriptions Dispensed Ranked by Leading Drugs for Asacol, Pentasa, Lialda, Canasa, Sulphasalazine, Colazal, Other Drugs and Generics (includes corresponding Graph/Chart)
Canada
Key Challenges Lie ahead
Productivity Loss to the Nation
Australia
Japan
Europe
Increasing Awareness to Drive Market Growth
United Kingdom
2.IBD - AN OVERVIEW
Prevalence and Incidence
Women More Susceptible to IBD
Etiology of Inflammatory Bowel Disease
Genetic Predisposition
Environmental Factors
IBD – A Health and Social Burden
Inflammatory Bowel Disease Types
Crohn's Disease (CD)
Ulcerative Colitis (UC)
Clinical Manifestations
Signs and Symptoms
Diagnosis
Pathogenesis
Outcomes
Treatment Strategies
Step I (Aminosalicylates)
5-AMINOSALICYLIC ACID (5-ASA) DERIVATIVES AND AVAILABLE BRANDS IN THE US MARKET
Step II (Antibiotics)
Step III (Corticosteroids)
Available Corticosteroidal Drugs As per Mode of Administration
Step IV (Immuno-modifying Agents)
Overview of Select Biological Drugs
Infliximab (Remicade)
Adalimumab (Humira)
Certolizumab pegol (Cimzia)
Natalizumab (Tysabri)
Step V (Experimental Medication)
Experimental Medication Drugs for IBD with Dosage Settings
Ileal Pouch recommended in Conditions of Ulcerative Colitis
Comparing Crohn’s Disease and Ulcerative Colitis
Comparison of Characteristics of Ulcerative Colitis and Crohn’s Disease
3.PRODUCT INNOVATIONS/LAUNCHES
Procter & Gamble Pharmaceuticals Introduces Asacol HD
Exagen Diagnostics Introduces eXaIBS Test and eXaIBD Test
Cimzia® Receives FDA Nod for Treating Crohn’s Disease
Kyorin Pharmaceutical Launches Pentasa Tablets 500
Xian-Janssen Introduces Remicade, Branded infliximab in China
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease
Salix and Watson to Launch COLAZAL® Authorized Generic
4.RECENT INDUSTRY ACTIVITY
GlaxoSmithKline Enters into Partnerships with Biotica, Dynavax, and Archemix
Sequenom Buys AttoSense Portfolio and Other Assets from SensiGen
Zeria Pharmaceutical to Take Over Tillotts Pharma
Meridian Bioscience Europe Signs Agreement with BUHLMANN Laboratories
Sosei Group Inks Deal with Biocopea
UCB Receives FDA Approval for Cimzia
Regeneron Pharmaceuticals and Sanofi-aventis Extend Global Collaboration
Celldex Therapeutics Acquires CuraGen
Onyx Pharmaceuticals Acquires Proteolix
Roche Acquires ARIUS Research, Inc.
Nycomed Inks Agreement with Immunomedics for Veltuzumab
Archemix Inks Deal with GlaxoSmithKline
Boehringer to Takeover Actimis
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals
The Asian Institute of Gastroenterology Establishes New facility
TPG Capital Acquires Axcan Pharma
Cosmo Pharmaceuticals Collaborates with Santarus
BioLineRx Inks License Agreement with Yissum
Salix Pharmaceuticals Secures FDA Approval for APRISO™
Omeros Inks Agreement with Affitech
GlaxoSmithKline Enters into Strategic Alliance with Regulus Therapeutics
Roche to Take Over Piramed
Evotec Acquires Renovis
Takeda Pharmaceutical Acquires Millennium Pharmaceuticals
GlaxoSmithKline Takes Over Sirtris Pharmaceuticals
Boehringer Ingelheim Inks Agreement with Actimis Pharmaceuticals
GlaxoSmithKline Enters into a Strategic Alliance with Archemix
Pipex Pharmaceuticals Buys Oral dnaJP1
Emergent BioSolutions Acquires AVANIR’s Anthrax Monoclonal Antibody Collection
Ferring Inks License Agreement with Conaris
ZymoGenetics and Merck Serono Restructure Their Partnership
Evotec Acquires Renovis
ViroPharma Acquires Lev Pharmaceuticals
TPG Capital Inks Agreement to Acquire Axcan Pharma
Meyer Pharmaceuticals Inks Agreement with AnGes
The School of Pharmacy Enters Into Collaboration with Tillotts Pharma
Sequenom Inks Collaborative Agreement with SensiGen
Evotec Signs Collaborative Agreement with Interprotein
Shire Obtains Approval from FDA for LIALDA™ (mesalamine)
Amgen Acquires Avidia
Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals
5.FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories (US)
Biogen Idec, Inc. (US)
Cosmo Pharmaceuticals SpA (Italy)
ChemoCentryx, Inc. (US)
Dr. Falk Pharma GmbH (Germany)
Eisai Co., Ltd. (Japan)
Elan Corporation, plc (Ireland)
Ferring Pharmaceuticals A/S (Denmark)
GlaxoSmithKline plc (UK)
Johnson & Johnson (US)
Centocor Ortho Biotech, Inc. (US)
Kyorin Pharmaceutical Co., Ltd. (Japan)
Merck Serono (Switzerland)
Millennium Pharmaceuticals, Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co. Ltd. (Japan)
Prometheus Laboratories, Inc. (US)
Shire Plc (UK)
UCB SA (Belgium)
Wyeth (US)
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 69 (including Divisions/Subsidiaries - 77)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
